Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 3;83(3):298–306. doi: 10.1054/bjoc.2000.1268

Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor

D Albo 1, V L Rothman 1, D D Roberts 2, G P Tuszynski 1
PMCID: PMC2374573  PMID: 10917542

Abstract

We have previously shown that platelet-produced thrombospondin-1 up-regulates the urokinase plasminogen activator and its receptor and promotes tumour cell invasion. Although tumour cells produce thrombospondin-1 in vivo, they produce only minimal amounts of thrombospondin-1 in vitro. To determine the effect of tumour cell-produced thrombospondin-1 in the regulation of the plasminogen/plasmin system and tumour cell invasion, we studied THBS-1 -transfected MDA-MB-435 breast cancer cells that overexpress thrombospondin-1. The role of urokinase plasminogen receptor in thrombospondin-1-mediated adhesion and invasion was studied by antisense inhibition, enzymatic cleavage and antibody neutralization. Tumour cell adhesion to collagen and laminin was evaluated. Tumour cell invasion was studied in a modified Boyden chamber collagen invasion assay. Tumour cell thrombospondin-1 induced a 2–7 fold increase in urokinase plasminogen activator receptor and cell-associated urokinase plasminogen activator expression and a 50–65% increase in cell-associated urokinase plasminogen activator and plasmin activities. Furthermore, tumour cell thrombospondin-1 promoted tumour cell invasion and decreased tumour cell adhesion through up-regulation of urokinase plasminogen activator receptor-controlled urokinase plasminogen activator and plasmin activities. We conclude that tumour cell-produced thrombospondin-1 may play a critical role in the regulation of tumour cell adhesion and tumour cell invasion. © 2000 Cancer Research Campaign

Keywords: urokinase plasminogen activator, plasmin, pericellular proteolysis

Full Text

The Full Text of this article is available as a PDF (126.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albini A., Iwamoto Y., Kleinman H. K., Martin G. R., Aaronson S. A., Kozlowski J. M., McEwan R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987 Jun 15;47(12):3239–3245. [PubMed] [Google Scholar]
  2. Albo D., Arnoletti J. P., Castiglioni A., Granick M. S., Solomon M. P., Rothman V. L., Tuszynski G. P. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun. 1994 Sep 15;203(2):857–865. doi: 10.1006/bbrc.1994.2262. [DOI] [PubMed] [Google Scholar]
  3. Albo D., Berger D. H., Tuszynski G. P. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. J Surg Res. 1998 Apr;76(1):86–90. doi: 10.1006/jsre.1998.5299. [DOI] [PubMed] [Google Scholar]
  4. Albo D., Berger D. H., Wang T. N., Hu X., Rothman V., Tuszynski G. P. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery. 1997 Aug;122(2):493–500. doi: 10.1016/s0039-6060(97)90043-x. [DOI] [PubMed] [Google Scholar]
  5. Arnoletti J. P., Albo D., Granick M. S., Solomon M. P., Castiglioni A., Rothman V. L., Tuszynski G. P. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer. 1995 Sep 15;76(6):998–1005. doi: 10.1002/1097-0142(19950915)76:6<998::aid-cncr2820760613>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  6. Arnoletti J. P., Albo D., Jhala N., Granick M. S., Solomon M. P., Atkinson B., Rothman V. L., Tuszynski G. P. Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am J Surg. 1994 Nov;168(5):433–436. doi: 10.1016/s0002-9610(05)80093-5. [DOI] [PubMed] [Google Scholar]
  7. Barnathan E. S., Kuo A., Karikó K., Rosenfeld L., Murray S. C., Behrendt N., Rønne E., Weiner D., Henkin J., Cines D. B. Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood. 1990 Nov 1;76(9):1795–1806. [PubMed] [Google Scholar]
  8. Bianchi E., Cohen R. L., Dai A., Thor A. T., Shuman M. A., Smith H. S. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer. 1995 Mar 3;60(5):597–603. doi: 10.1002/ijc.2910600505. [DOI] [PubMed] [Google Scholar]
  9. Blasi F., Behrendt N., Cubellis M. V., Ellis V., Lund L. R., Masucci M. T., Møller L. B., Olson D. P., Pedersen N., Ploug M. The urokinase receptor and regulation of cell surface plasminogen activation. Cell Differ Dev. 1990 Dec 2;32(3):247–253. doi: 10.1016/0922-3371(90)90037-w. [DOI] [PubMed] [Google Scholar]
  10. Blasi F. Molecular mechanisms of protease-mediated tumor invasiveness. J Surg Oncol Suppl. 1993;3:21–23. [PubMed] [Google Scholar]
  11. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993 Feb;15(2):105–111. doi: 10.1002/bies.950150206. [DOI] [PubMed] [Google Scholar]
  12. Busso N., Masur S. K., Lazega D., Waxman S., Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol. 1994 Jul;126(1):259–270. doi: 10.1083/jcb.126.1.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Clezardin P., Frappart L., Clerget M., Pechoux C., Delmas P. D. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res. 1993 Mar 15;53(6):1421–1430. [PubMed] [Google Scholar]
  14. Clezardin P., Serre C. M., Trzeciak M. C., Drouin J., Delmas P. D. Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction. Cancer Res. 1991 May 15;51(10):2621–2627. [PubMed] [Google Scholar]
  15. Costantini V., Sidoni A., Deveglia R., Cazzato O. A., Bellezza G., Ferri I., Bucciarelli E., Nenci G. G. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer. 1996 Mar 15;77(6):1079–1088. doi: 10.1002/(sici)1097-0142(19960315)77:6<1079::aid-cncr12>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  16. Ellis V., Behrendt N., Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem. 1991 Jul 5;266(19):12752–12758. [PubMed] [Google Scholar]
  17. Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Bontenbal M., Jänicke F., Klijn J. G. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992 Nov 1;52(21):6101–6105. [PubMed] [Google Scholar]
  18. Grossfeld G. D., Ginsberg D. A., Stein J. P., Bochner B. H., Esrig D., Groshen S., Dunn M., Nichols P. W., Taylor C. R., Skinner D. G. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997 Feb 5;89(3):219–227. doi: 10.1093/jnci/89.3.219. [DOI] [PubMed] [Google Scholar]
  19. Grøndahl-Hansen J., Hilsenbeck S. G., Christensen I. J., Clark G. M., Osborne C. K., Brünner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr;43(2):153–163. doi: 10.1023/a:1005744914124. [DOI] [PubMed] [Google Scholar]
  20. Hajjar K. A. Cellular receptors in the regulation of plasmin generation. Thromb Haemost. 1995 Jul;74(1):294–301. [PubMed] [Google Scholar]
  21. Hosokawa T., Muraishi A., Rothman V. L., Papale M., Tuszynski G. P. The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma. Oncol Res. 1993;5(4-5):183–189. [PubMed] [Google Scholar]
  22. Hébert C. A., Baker J. B. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol. 1988 Apr;106(4):1241–1247. doi: 10.1083/jcb.106.4.1241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Karikó K., Kuo A., Boyd D., Okada S. S., Cines D. B., Barnathan E. S. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res. 1993 Jul 1;53(13):3109–3117. [PubMed] [Google Scholar]
  24. Keski-Oja J., Koli K., Lohi J., Laiho M. Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin Thromb Hemost. 1991 Jul;17(3):231–239. doi: 10.1055/s-2007-1002614. [DOI] [PubMed] [Google Scholar]
  25. Kook Y. H., Adamski J., Zelent A., Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 1994 Sep 1;13(17):3983–3991. doi: 10.1002/j.1460-2075.1994.tb06714.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Krishnamurti C., Alving B. M. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost. 1992 Jan;18(1):67–80. doi: 10.1055/s-2007-1002412. [DOI] [PubMed] [Google Scholar]
  27. Laiho M., Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res. 1989 May 15;49(10):2533–2553. [PubMed] [Google Scholar]
  28. Mignatti P., Rifkin D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993 Jan;73(1):161–195. doi: 10.1152/physrev.1993.73.1.161. [DOI] [PubMed] [Google Scholar]
  29. Mohanam S., Sawaya R. E., Yamamoto M., Bruner J. M., Nicholson G. L., Rao J. S. Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. J Neurooncol. 1994;22(2):153–160. doi: 10.1007/BF01052890. [DOI] [PubMed] [Google Scholar]
  30. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J. S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993 Sep 15;53(18):4143–4147. [PubMed] [Google Scholar]
  31. Nathan F. E., Hernandez E., Dunton C. J., Treat J., Switalska H. I., Joseph R. R., Tuszynski G. P. Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer. 1994 Jun 1;73(11):2853–2858. doi: 10.1002/1097-0142(19940601)73:11<2853::aid-cncr2820731131>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  32. Ossowski L., Clunie G., Masucci M. T., Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol. 1991 Nov;115(4):1107–1112. doi: 10.1083/jcb.115.4.1107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res. 1992 Dec 15;52(24):6754–6760. [PubMed] [Google Scholar]
  34. Ploug M., Kjalke M., Rønne E., Weidle U., Høyer-Hansen G., Danø K. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem. 1993 Aug 15;268(23):17539–17546. [PubMed] [Google Scholar]
  35. Plow E. F., Freaney D. E., Plescia J., Miles L. A. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol. 1986 Dec;103(6 Pt 1):2411–2420. doi: 10.1083/jcb.103.6.2411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pöllänen J., Hedman K., Nielsen L. S., Danø K., Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol. 1988 Jan;106(1):87–95. doi: 10.1083/jcb.106.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Pöllänen J., Saksela O., Salonen E. M., Andreasen P., Nielsen L., Danø K., Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol. 1987 Apr;104(4):1085–1096. doi: 10.1083/jcb.104.4.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Roldan A. L., Cubellis M. V., Masucci M. T., Behrendt N., Lund L. R., Danø K., Appella E., Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990 Feb;9(2):467–474. doi: 10.1002/j.1460-2075.1990.tb08132.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Roth J. J., Reiver D. M., Granick M. S., Rothman V. L., Nicosia R. F., Tuszynski G. P. Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors. Histol Histopathol. 1997 Oct;12(4):1013–1018. [PubMed] [Google Scholar]
  40. Schultz-Cherry S., Lawler J., Murphy-Ullrich J. E. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem. 1994 Oct 28;269(43):26783–26788. [PubMed] [Google Scholar]
  41. Schultz-Cherry S., Murphy-Ullrich J. E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol. 1993 Aug;122(4):923–932. doi: 10.1083/jcb.122.4.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Schultz-Cherry S., Ribeiro S., Gentry L., Murphy-Ullrich J. E. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem. 1994 Oct 28;269(43):26775–26782. [PubMed] [Google Scholar]
  43. Seiffert D., Ciambrone G., Wagner N. V., Binder B. R., Loskutoff D. J. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem. 1994 Jan 28;269(4):2659–2666. [PubMed] [Google Scholar]
  44. Testa J. E., Quigley J. P. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev. 1990 Dec;9(4):353–367. doi: 10.1007/BF00049524. [DOI] [PubMed] [Google Scholar]
  45. Tuszynski G. P., Gasic T. B., Rothman V. L., Knudsen K. A., Gasic G. J. Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res. 1987 Aug 1;47(15):4130–4133. [PubMed] [Google Scholar]
  46. Tuszynski G. P., Murphy A. Spectrophotometric quantitation of anchorage-dependent cell numbers using the bicinchoninic acid protein assay reagent. Anal Biochem. 1990 Jan;184(1):189–191. doi: 10.1016/0003-2697(90)90032-5. [DOI] [PubMed] [Google Scholar]
  47. Tuszynski G. P., Nicosia R. F. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab Invest. 1994 Feb;70(2):228–233. [PubMed] [Google Scholar]
  48. Tuszynski G. P., Nicosia R. F. The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays. 1996 Jan;18(1):71–76. doi: 10.1002/bies.950180113. [DOI] [PubMed] [Google Scholar]
  49. Tuszynski G. P., Rothman V., Murphy A., Siegler K., Smith L., Smith S., Karczewski J., Knudsen K. A. Thrombospondin promotes cell-substratum adhesion. Science. 1987 Jun 19;236(4808):1570–1573. doi: 10.1126/science.2438772. [DOI] [PubMed] [Google Scholar]
  50. Tuszynski G. P., Smith M., Rothman V. L., Capuzzi D. M., Joseph R. R., Katz J., Besa E. C., Treat J., Switalska H. I. Thrombospondin levels in patients with malignancy. Thromb Haemost. 1992 Jun 1;67(6):607–611. [PubMed] [Google Scholar]
  51. Tuszynski G. P., Wang T. N., Berger D. Adhesive proteins and the hematogenous spread of cancer. Acta Haematol. 1997;97(1-2):29–39. doi: 10.1159/000203657. [DOI] [PubMed] [Google Scholar]
  52. Vassalli J. D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985 Jan;100(1):86–92. doi: 10.1083/jcb.100.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Vassalli J. D., Sappino A. P., Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991 Oct;88(4):1067–1072. doi: 10.1172/JCI115405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wang T. N., Qian X. H., Granick M. S., Solomon M. P., Rothman V. L., Berger D. H., Tuszynski G. P. Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery. 1996 Aug;120(2):449–454. doi: 10.1016/s0039-6060(96)80322-9. [DOI] [PubMed] [Google Scholar]
  55. Wang T. N., Qian X. H., Granick M. S., Solomon M. P., Rothman V. L., Tuszynski G. P. The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen. Am J Surg. 1995 Nov;170(5):502–505. doi: 10.1016/s0002-9610(99)80340-7. [DOI] [PubMed] [Google Scholar]
  56. Wang T. N., Qian X., Granick M. S., Solomon M. P., Rothman V. L., Berger D. H., Tuszynski G. P. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res. 1996 Jun;63(1):39–43. doi: 10.1006/jsre.1996.0219. [DOI] [PubMed] [Google Scholar]
  57. Wang T. N., Qian X., Granick M. S., Solomon M. P., Rothman V. L., Berger D. H., Tuszynski G. P. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res. 1996 Jun;63(1):39–43. doi: 10.1006/jsre.1996.0219. [DOI] [PubMed] [Google Scholar]
  58. Weinstat-Saslow D. L., Zabrenetzky V. S., VanHoutte K., Frazier W. A., Roberts D. D., Steeg P. S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994 Dec 15;54(24):6504–6511. [PubMed] [Google Scholar]
  59. Wong S. Y., Purdie A. T., Han P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am J Pathol. 1992 Jun;140(6):1473–1482. [PMC free article] [PubMed] [Google Scholar]
  60. Yabkowitz R., Mansfield P. J., Dixit V. M., Suchard S. J. Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. Cancer Res. 1993 Jan 15;53(2):378–387. [PubMed] [Google Scholar]
  61. Yamashita Y., Kurohiji T., Tuszynski G. P., Sakai T., Shirakusa T. Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer. 1998 Feb 15;82(4):632–638. doi: 10.1002/(sici)1097-0142(19980215)82:4<632::aid-cncr3>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  62. Yu W., Kim J., Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol. 1997 May 5;137(3):767–777. doi: 10.1083/jcb.137.3.767. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES